Arcus Biosciences, Inc.
RCUS · NYSE
Company research
Arcus Biosciences, Inc. (NYSE: RCUS) is a clinical-stage, global biopharmaceutical company founded in 2015 and headquartered in Hayward, California, focused on developing differentiated molecules and combination therapies for people with cancer. The company maintains a broad and diversified oncology pipeline that includes Domvanalimab (anti-TIGIT antibody), Casdatifan (HIF-2α inhibitor for kidney cancer), Quemliclustat (CD73 inhibitor targeting the ATP-adenosine pathway), and Zimberelimab (anti-PD-1 antibody), among other candidates spanning Phase 1 through Phase 3 clinical trials across lung, gastrointestinal, pancreatic, and kidney cancers. Arcus has established a key clinical collaboration with AstraZeneca, including the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 non-small cell lung cancer, underscoring its strategy of leveraging strategic partnerships to accelerate development of first- or best-in-class medicines. With approximately 601 full-time employees and a market capitalization of roughly $3.1 billion, Arcus continues to generate growing collaboration revenues while investing heavily in its pipeline to address significant unmet medical needs in oncology.
Research reports
AI-driven equity report assigning RCUS an AI Score of 7/10 (Buy) and a +8.07% probability advantage of beating the S&P 500 over three months, supported by positive momentum, valuation, earnings quality and sentiment factors while flagging weak profitability and elevated volatility as key risks.
ChartMill · December 17, 2025ARCUS BIOSCIENCES INC (RCUS) Stock Fundamental AnalysisAutomated fundamental report rating RCUS 2/10 overall and 0/10 on valuation, highlighting very poor profitability (ROA around -35% and ROE around -78%), an expensive valuation relative to biotech peers, and an expected EPS decline of roughly 19.8% over the next year, leading to a cautions, downside‑skewed view despite medium growth prospects.
Koala Gains · November 3, 2025Arcus Biosciences, Inc. (RCUS) Future Performance AnalysisLong-horizon scenario analysis treating RCUS as a high‑risk, high‑reward clinical-stage biotech whose value is largely binary, modeling normal, bull and bear revenue trajectories through 2035 and emphasizing that trial success could make Arcus a multi‑billion‑revenue oncology player while failure of lead programs could erase most shareholder value.
DirectorsTalk Interviews · August 14, 2025Arcus Biosciences, Inc. (RCUS) Stock Analysis: Exploring a Potential 186% Upside in BiotechnologyNarrative stock analysis highlighting Arcus’s oncology pipeline (including casdatifan and domvanalimab), collaborations such as AstraZeneca’s PACIFIC‑8 trial, and an average analyst price target of about 28.36 implying roughly 186% upside, while acknowledging share price volatility, persistent losses, and typical clinical-stage biotech execution risks.